Young Wook Choi

Dr. Young Wook Choi

Department of Urology, Chung-Ang University College of Medicine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2017 in Clinical Proteomics
Verified
Journal Article
Open access
PDF file
YCYoung Wook Choi
Young Wook Choi
YKYang Gyun Kim
Yang Gyun Kim
MSMin-Young Song
Min-Young Song
JMJu-Young Moon
Ju-Young Moon
KJKyung Hwan Jeong
Kyung Hwan Jeong
SLSang Ho Lee
Sang Ho Lee
Nephrotic syndrome (NS) is a nonspecific kidney disorder, commonly caused by minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN). Here we analyzed urinary protein profiles, aiming to discover disease-specific biomarkers of these three common diseases in NS. Sixteen urine samples were collected from patients with biopsy-proven NS and healthy controls. After removal of high-abundance proteins, the urinary protein profile was analyzed by LC–MS/MS to generate a discovery set. For validation, ELISA was used to analyze the selected proteins in 61 urine samples. The discovery set included 228 urine proteins, of which 22 proteins were differently expressed in MCD, MN, and FSGS. Among these, C9, CD14, and SERPINA1 were validated by ELISA. All three proteins were elevated in MCD, MN, and FSGS groups compared with in IgA nephropathy and healthy controls. When a regression model was applied, receiver operating characteristic analysis clearly discriminated MCD from the other causative diseases in NS. We developed a disease-specific protein panel that discriminated between three main causes of NS. Through this pilot study, we suggest that urine proteomics could be a non-invasive and clinically available tool to discriminate MCD from MN and FSGS.

Verified
Journal Article
Open access
PDF file
JKJung Hoon Kim
Jung Hoon Kim
Seungjin LeeSeungjin Lee
Seungjin Lee
SKSu Jeong Kang
Su Jeong Kang
YCYoung Wook Choi
Young Wook Choi
SCSe Young Choi
Se Young Choi
ICIn Ho Chang
In Ho Chang
Immunotherapy of bladder cancer is known to have favorable effects, although it is difficult to determine which patients will show a good response because of the different tumor microenvironments (TME). Here, we developed a bladder cancer-on-a-chip (BCOC) to mimic the TME using three-dimensional (3D) bioprinting and microfluidic technology. We fabricated a T24 and a 5637-cell line-based BCOC that also incorporated MRC-5, HUVEC, and THP-1 cells. We evaluated the effects of TME and assessed the immunologic reactions in response to different concentrations of Bacillus Calmette–Guérin (BCG) via live/dead assay and THP-1 monocytic migration, and concentrations of growth factors and cytokines. The results show that cell viability was maintained at 15% filling density in circle-shaped cell constructs at 20 μL/min microfluidic flow rate. A 3D co-culture increased the proliferation of BCOCs. We found that the appropriate time to evaluate the viability of BCOC, concentration of cytokines, and migration of monocytes was 6 h, 24 h, and three days after BGC treatment. Lastly, the immunotherapeutic effects of BCOC increased according to BCG dosage. To predict effects of immunotherapeutic agent in bladder cancer, we constructed a 3D bioprinted BCOC model. The BCOC was validated with BCG, which has been proven to be effective in the immunotherapy of bladder cancer.

1 January 2022 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
JKJung Hoon Kim
Jung Hoon Kim
JCJoongwon Choi
Joongwon Choi
MKMirinae Kim
Mirinae Kim
SKSu Jeong Kang
Su Jeong Kang
YCYoung Wook Choi
Young Wook Choi
ICIn Ho Chang
In Ho Chang
Kim JH, et al. Investig Clin Urol. 2022 Mar;63(2):228-237. https://doi.org/10.4111/icu.20210425

1 January 2023 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
JCJoongwon Choi
Joongwon Choi
TJTae Young Jung
Tae Young Jung
JKJung Hoon Kim
Jung Hoon Kim
SMSejung Maeng
Sejung Maeng
SKSu Jeong Kang
Su Jeong Kang
ICIn Ho Chang
In Ho Chang
Choi J, et al. Investig Clin Urol. 2023 Mar;64:e15. https://doi.org/10.4111/icu.20220293

30 November 2022 in The Korean Journal of Urological Oncology
Verified
Journal Article
Open access
PDF file
JSJeong Yoon Suh
Jeong Yoon Suh
SMSe Jung Maeng
Se Jung Maeng
MKMirinae Kim
Mirinae Kim
SKSu Jeong Kang
Su Jeong Kang
YCYoung Wook Choi
Young Wook Choi
ICIn Ho Chang
In Ho Chang
Clear cell renal cell carcinoma (ccRCC) is a disease with a wide variety of clinical progressions such as the rate of disease progression or the degree of metastasis. About 30% of ccRCC patients suffer from metastatic diseases, and about 30% develop metastasis after diagnosis. In the case of metastatic RCC, early prediction of the disease is important because of the poor prognosis, but ccRCC-specific molecular markers for clinical use are not available yet. As an alternative, liquid biopsy, which can find molecules released from tumor tissues in circulating blood and obtain information on metastatic dissemination and recurrence of ccRCC, is emerging. In this article, we will introduce molecules such as cell free DNA, cell free RNA, protein, and exosomes available as circulating biomarkers for liquid biopsy. We will also introduce some promising technologies that can compensate for the limitations of liquid biopsy.

28 February 2021 in The Korean Journal of Urological Oncology
Verified
Journal Article
Open access
PDF file
DCDa Som Choi
Da Som Choi
SKSu Jeong Kang
Su Jeong Kang
ICIn Ho Chang
In Ho Chang
YCYoung Wook Choi
Young Wook Choi